RTP Mobile Logo
RTP TV: Part IV — Multiple Myeloma (MM): Novel Agents and New Paradigms
Released July 2011

In this, the fourth part (originally held July 5, 2011) of our eight-part online, integrated educational course, Drs Nikhil C Munshi and A Keith Stewart discuss recent advances in the treatment of MM. (Webinar)

CE Disclosures and Faculty Information


    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MM.


    MM is a plasma cell neoplasm that accounts for approximately 10 percent of all hematologic cancer and carries with it the worst death/new cases ratio (3:4) among the whole of the blood cancer subtypes. The development of molecular-targeted agents and alternative chemotherapeutics for the treatment of MM has been the focus of extensive research and has resulted in the emergence of clinical scenarios in which multiple treatment options may be available. Controversy persists in several areas of patient care, such as selection of the optimal induction therapy for transplant and nontransplant candidates and post-transplant maintenance strategies. This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians in the formulation of up-to-date and appropriate treatment strategies.


    • Integrate the results of new clinical research into the selection of optimal systemic therapy for patients with MM, both eligible and ineligible for stem cell transplant.
    • Use evidence-based clinical and molecular factors to tailor maintenance treatment recommendations.
    • Compare and contrast existing IMiDs and proteasome inhibitors with their experimental next-generation counterparts.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Nikhil C Munshi, MD
    Associate Professor of Medicine, Harvard Medical School
    Associate Director, Jerome Lipper Multiple Myeloma Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

    A Keith Stewart, MBChB
    Dean for Research
    Polak Professor of Cancer Research
    Mayo Clinic in Arizona
    Scottsdale, Arizona

    Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Paid Research: Millennium: The Takeda Oncology Company.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2011
    Expiration date: July 2012


Acknowledge and close

Watch Video
(WiFi is recommended for best performance):